Molecular alterations in key-regulator genes among patients with T4 breast carcinoma

Department of Medical Oncology, University of Cagliari, Cagliari, Italy.
BMC Cancer (Impact Factor: 3.36). 08/2010; 10(1):458. DOI: 10.1186/1471-2407-10-458
Source: PubMed


Prognostic factors in patients who are diagnosed with T4 breast carcinomas are widely awaited. We here evaluated the clinical role of some molecular alterations involved in tumorigenesis in a well-characterized cohort of T4 breast cancer patients with a long follow-up period.
A consecutive series of 53 patients with T4 breast carcinoma was enrolled between 1992 and 2001 in Sardinia, and observed up for a median of 125 months. Archival paraffin-embedded tissue sections were used for immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses, in order to assess alterations in expression levels of survivin, p53, and pERK1-2 proteins as well as in amplification of CyclinD1 and h-prune genes. The Kaplan-Meier and Cox regression methods were used for survival assessment and statistical analysis.
Overall, patients carrying increased expression of pERK1-2 (p = 0.027) and survivin (p = 0.008) proteins as well as amplification of h-prune gene (p = 0.045) presented a statistically-significant poorer overall survival in comparison with cases found negative for such alterations. After multivariate analysis, the pathological response to primary chemotherapy and the survivin overexpression in primary carcinoma represented the main parameters with a role as independent prognostic factors in our series.
Although retrospective, our study identified some molecular parameters with a significant impact on prediction of the response to therapy or prognosis among T4 breast cancer patients. Further large prospective studies are needed in order to validate the use of such markers for the management of these patients.

Download full-text


Available from: Antonio Cossu
  • Source
    • "Among the several interacting proteins with Nm23- H1, H-Prune has been well characterized. H-Prune belongs to the phosphoesterase (DHH) protein super-family, and its enhanced expression in colorectal, breast, and gastric cancers associates with the degree of lymph node and distant metastasis (Massidda et al. 2010). H-Prune sequence comprises two domains at the N-terminus such as DHH and DHHA2 domains which are involved in its enzymatic functions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Metastasis is the most common cause of cancer mortality. To increase the survival of patients, it is necessary to develop more effective methods for treating as well as preventing metastatic diseases. Recent advancement of knowledge in cancer metastasis provides the basis for devel-opment of targeted molecular therapeutics aimed at the tumor cell or its interaction with the host microenvironment. Metas-tasis suppressor genes (MSGs) are promising targets for inhi-bition of the metastasis process. During the past decade, functional significance of these genes, their regulatory path-ways, and related downstream effector molecules have be-come a major focus of cancer research. Nm23-H1, first in the family of Nm23 human homologues, is a well-characterized, anti-metastatic factor linked with a large number of human malignancies. Mounting evidence to date suggests an impor-tant role for Nm23-H1 in reducing virus-induced tumor cell motility and migration. A detailed understanding of the mo-lecular association between oncogenic viral antigens with Nm23-H1 may reveal the underlying mechanisms for tumor virus-associated malignancies. In this review, we will focus on the recent advances to our understanding of the molecular basis of oncogenic virus-induced progression of tumor metas-tasis by deregulation of Nm23-H1.
    Full-text · Article · Sep 2014 · Archiv für Experimentelle Pathologie und Pharmakologie
  • Source
    • "This study has indeed been focused on the different delivery of an intrinsically disordered C-terminal domain of h-prune20 fused to TAT and gH625. H-prune is a member of the DHH protein super-family, overexpressed in breast, colorectal, and gastric cancers.21–24 H-prune possesses a hitherto phosphodiesterase (cAMP-PDE) activity, and inhibition of PDE activity with dipyridamole suppresses cell motility in breast cell lines.25,26 "
    [Show abstract] [Hide abstract]
    ABSTRACT: A genetically modified recombinant gH625-c-prune was prepared through conjugation of c-prune with gH625, a peptide encompassing 625-644 residues of the glycoprotein H of herpes simplex virus 1, which has been proved to possess the ability to carry cargo molecules across cell membranes. C-prune is the C-terminal domain of h-prune, overexpressed in breast, colorectal, and gastric cancers, interacting with multiple partners, and representing an ideal target for inhibition of cancer development. Its C-terminal domain results in an intrinsically disordered domain (IDD), and the peculiar properties of gH625 render it an optimal candidate to act as a carrier for this net negatively charged molecule by comparison with the positively charged TAT. A characterization of the recombinant gH625-c-prune fusion protein was conducted by biochemical, cellular biology and confocal microscopy means in comparison with TAT-c-prune. The results showed that the gH625-c-prune exhibited the ability to cross biomembranes, opening a new scenario on the use of gH625 as a novel multifunctional carrier.
    Full-text · Article · Jul 2013 · International Journal of Nanomedicine
  • Source
    • "Several proteins that interact with Nm23-H1 have been identified, and among these, h-Prune has been the best characterized. The h-Prune protein is a member of the phosphoesterases (DHH) protein superfamily, and its overexpression in breast, colorectal and gastric cancers correlates with the degree of lymph-node and distant metastases21222324. The N-terminus of the h-Prune sequence contains the DHH (amino acids 10–180) and DHHA2 (amino acids 215-360) domains that are involved in its enzymatic functions. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nm23-H1 is one of the most interesting candidate genes for a relevant role in Neuroblastoma pathogenesis. H-Prune is the most characterized Nm23-H1 binding partner, and its overexpression has been shown in different human cancers. Our study focuses on the role of the Nm23-H1/h-Prune protein complex in Neuroblastoma. Using NMR spectroscopy, we performed a conformational analysis of the h-Prune C-terminal to identify the amino acids involved in the interaction with Nm23-H1. We developed a competitive permeable peptide (CPP) to impair the formation of the Nm23-H1/h-Prune complex and demonstrated that CPP causes impairment of cell motility, substantial impairment of tumor growth and metastases formation. Meta-analysis performed on three Neuroblastoma cohorts showed Nm23-H1 as the gene highly associated to Neuroblastoma aggressiveness. We also identified two other proteins (PTPRA and TRIM22) with expression levels significantly affected by CPP. These data suggest a new avenue for potential clinical application of CPP in Neuroblastoma treatment.
    Full-text · Article · Mar 2013 · Scientific Reports
Show more